SARS-CoV-2-Triggered Hemophagocytic Lymphohistiocytosis with Complications of Posterior Reversible Encephalopathy Syndrome.
Ross M PerryScott D CaseyAlex Q LeeSylvia P BowditchMary A RasmussenViyeka SethiArun R PanigrahiPublished in: Case reports in pediatrics (2024)
In this article, we describe a novel case of SARS-CoV-2-associated-hemophagocytic lymphohistiocytosis (HLH) complicated by posterior reversible encephalopathy syndrome (PRES). Initially diagnosed with multisystem inflammatory response in children (MIS-C), the patient received a large corticosteroid dose days before the onset of neurological symptoms. After developing PRES, the patient was treated with antihypertensives, antiepileptics, dexamethasone, and anakinra, leading to neurologic normalization. We propose that given the challenging diagnostic picture of PRES developing in patients with HLH or MIS-C, institutionalized standards for blood pressure management during corticosteroid induction may significantly improve outcomes in patients being treated for hyperinflammatory syndromes who develop neurological symptoms.
Keyphrases
- sars cov
- case report
- inflammatory response
- newly diagnosed
- blood pressure
- end stage renal disease
- respiratory syndrome coronavirus
- early onset
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- young adults
- low dose
- prognostic factors
- heart rate
- toll like receptor
- insulin resistance
- adipose tissue
- depressive symptoms
- lps induced
- brain injury
- blood brain barrier